✦ LIBER ✦

Current and future anti-TNF therapy for inflammatory bowel disease

✍ Scribed by Mark T. Osterman; Gary R. Lichtenstein

Publisher: Springer
Year: 2007
Tongue: English
Weight: 168 KB
Volume: 10
Category: Article
ISSN: 1092-8472
DOI: 10.1007/s11938-007-0013-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Future therapies for inflammatory bowel

Future therapies for inflammatory bowel disease

✍ Stephen J. Bickston; Lawrence W. Comerford; Fabio Cominelli 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 303 KB

Tuberculous chemoprophylaxis requirement

Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy

✍ Yamile Zabana; Eugeni Domènech; Antonio López San Román; Belén Beltrán; José Lui 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Background: Preventive actions are advised since the use of anti-tumor necrosis factor (TNF) agents is known to increase the risk of tuberculosis (TB). No data related to the effectiveness and safety of the preventive chemoprophylaxis (ChP) for TB in inflammatory bowel disease (IBD) patients are ava

ChemInform Abstract: Targeting Therapy f

ChemInform Abstract: Targeting Therapy for Inflammatory Diseases by anti-TNFα Biologics

✍ Takahisa Sugita 📂 Article 📅 2009 🏛 John Wiley and Sons ⚖ 16 KB 👁 1 views

The role of antibiotic and probiotic the

The role of antibiotic and probiotic therapies in current and future management of inflammatory Bowel disease

✍ Julia B. Ewaschuk; Qassim Z. Tejpar; Isaac Soo; Karen L. Madsen; Richard N. Fedo 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 171 KB

Liver diseases associated with anti-tumo

Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease

✍ Carla S. Coffin; Hughie F. Fraser; Remo Panaccione; Subrata Ghosh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

The conventional treatment of inflammatory bowel disease (IBD) has focused on nonspecifically targeting mucosal inflammation. In the last decade, with the advent of novel biological agents that directly inhibit proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-a), rapid progress ha

Mycophenolate mofetil therapy for refrac

Mycophenolate mofetil therapy for refractory inflammatory bowel disease

✍ S. Palaniappan; A. C. Ford; D. Greer; S. M. Everett; D. M. Chalmers; A. T. R. Ax 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

Background: Mycophenolate mofetil (MMF) is an immunomodulatory drug, and its use in inflammatory bowel disease has previously been reported. The aim of this study was to review the Leeds Colitis Clinic experience of the safety and efficacy of MMF in treating patients with refractory Crohn's disease